ABT-199 (Venetoclax) and BCL-2 Inhibitors in Clinical Development

Authors

Shundong Cang, Department of Oncology, The Henan Province People's Hospital, Zhengzhou, China.
Chaitanya Iragavarapu, Department of Medicine, Westchester Medical Center and New York Medical College, Valhalla, New York, 10595, USA.
John Savooji, Department of Medicine, Westchester Medical Center and New York Medical College, Valhalla, New York, 10595, USA.
Yongping Song, Henan Cancer Hospital and the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China.
Delong Liu, Henan Cancer Hospital and the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China. delong_liu@nymc.edu.

Author Type(s)

Faculty

DOI

10.1186/s13045-015-0224-3

Journal Title

Journal of Hematology & Oncology

First Page

129

Document Type

Article

Publication Date

11-20-2015

Abstract

With the advent of new agents targeting CD20, Bruton's tyrosine kinase, and phosphoinositol-3 kinase for chronic lymphoid leukemia (CLL), more treatment options exist than ever before. B-cell lymphoma-2 (BCL-2) plays a major role in cellular apoptosis and is a druggable target. Small molecule inhibitors of BCL-2 are in active clinical studies. ABT-199 (venetoclax, RG7601, GDC-0199) has been granted breakthrough designation by FDA for relapsed or refractory CLL with 17p deletion. In this review, we summarized the latest clinical development of ABT-199/venetoclax and other novel agents targeting the BCL-2 proteins.

Recommended Citation

Cang, S., Iragavarapu, C., Savooji, J., Song, Y., & Liu, D. (2015). ABT-199 (Venetoclax) and BCL-2 Inhibitors in Clinical Development. Journal of Hematology & Oncology, 8, 129. https://doi.org/10.1186/s13045-015-0224-3